The efficacy of fixed dose rate infusion of gemcitabine combined with IFN-α2a in patients with advanced refractory renal cell carcinoma

Journal of Interferon and Cytokine Research

Volumn 25, Issue 3, 2005, Pages 165-168

  Massacesi, Cristian ^a   Burattini, Luciano ^a   Marcucci, Fabiana ^a   Bonsignori, Maurizio ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; GEMCITABINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADULT; AGED; ALOPECIA; ARTICLE; CEREBROVASCULAR ACCIDENT; CHEMOTHERAPY; CLINICAL ARTICLE; CONSTIPATION; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG MECHANISM; EDEMA; FATIGUE; FEMALE; FLU LIKE SYNDROME; HUMAN; IMMUNOTHERAPY; INFUSION; KIDNEY CARCINOMA; LEUKOPENIA; MALE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING; CHEMICALLY INDUCED DISORDER; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TUMOR; MIDDLE AGED; PROSPECTIVE STUDY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; DEOXYCYTIDINE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INTERFERON ALFA-2A; KIDNEY NEOPLASMS; LEUKOPENIA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; THROMBOCYTOPENIA;

EID: 14844339007     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2005.25.165     Document Type: Article

References (15)

1. NOBLE, S., and GOA, K.L. (1997). Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs 54, 447-472.
2. HEINEMANN, V., HERTEL, L.W., GRINDEY, G.B., and PLUNKETT, W. (1988). Comparison of the cellular pharmacokinetics and toxicity of 2′-2′- difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res. 48, 4024-4031.
3. HEINEMANN, V., XU, Y.-Z., CHUBB, S., SEN, A., HERTEL, L.W., GRINDEY, G.B., and PLUNKETT, W. (1990). Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′-2′-difluorodeoxycytidine. Mol. Pharmacol. 38, 567-572.
4. ABBRUZZESE, J.L., GRUNEWALD, R., WEEKS, E.A., GRAVEL, D., ADAMS, T., NOWAK, B., MINEISHI, S., TARASSOFF, P., SATTERLEE, W., and RABER, M.N. (1991). A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J. Clin. Oncol. 9, 491-498.
5. GRUNEWALD, R., ABBRUZZESE, J.L., TARASSOFF, P., and PLUNKETT, W. (1991). Saturation of 2′-2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during phase I trial of gemcitabine. Cancer Chemother. Pharmacol. 27, 258-262.
6. GRUNEWALD, R., KANTARJIAN, H., KEATING, M.J., ABBRUZZESE, J., TARASSOFF, P., and PLUNKETT, W. (1990). Pharmacologically directed design of the dose rate and schedule of 2′-2′-difluorodeoxycytidine (gemcitabine) administration in leukemia. Cancer Res. 50, 6823-6826.
7. TEMPERO, M., PLUNKETT, W., RUIZ VAN HAPEREN, V., HAINSWORTH, J., HOCHSTER, H., LENZI, R., and ABBRUZZESE, J. (2003). Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J. Clin. Oncol. 21, 3402-3408.
8. QUESADA, J.R. (1989). Role of interferons in the therapy of metastatic renal cell carcinoma. Urology 34, 87-96.
9. COCKCROFT, D.W., and GAULT, M.H. (1976). Prediction of creatinine clearence from serum creatinine. Nephron 16, 31-41.
10. NOWAK, A.K., ROBINSON, B.W.S., and LAKE, R.A. (2002). Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res. 62, 2353-2358.
11. DAIKELER, T., MAAS, K., BURKHARD, W., HARTMANN, J.-T., KNOBLOCH, A., ARNING, M., KANZ, L., and BOKEMEYER, C. (1997). The influence of gemcitabine on the CD4/CD8 ratio in patients with solid tumors. Oncol. Rep. 4, 561-564.
12. SOLORZANO, C.C., HWANG, R., BAKER, C.H., BUCANA, C.D., PISTERS, P.W., EVANS, D.B., KILLION, J.J., and FIDLER, I.J. (2003). Administration of optimal biological dose and schedule of interferon alpha combined with gemcitabine induces apoptosis in tumor-associated endothelial cells and reduces growth of human pancreatic carcinoma implanted orthotopically in nude mice. Clin. Cancer Res. 9, 1858-1867.
13. ROHDE, D., THIEMANN. D., WILDBERGER, J., WOLFF, J., and JAKSE, G. (1998). Treatment of renal cancer patients with gemcitabine (2′,2′- difluorodeoxycytidine) and interferons: antitumor activity and toxicity. Oncol. Rep. 5, 1555-1560.
14. FUXIUS, S., MROSS, K., MANSOURI, K., and UNGER, C. (2002). Gemcitabine and interferon-alpha 2b in solid tumors: a phase I study in patients with advanced or metastatic non-small cell lung, ovarian, pancreatic or renal cancer. Anticancer Drugs 13, 899-905.
15. AZZOLI, C.G., MILLER, V.A., NG, K.K., KRUG, L.M., HENSLEY, M.L., O'REILLY, E.M., MULLER, R.J., and KRIS, M.G. (2003). Gemcitabine-induced peripheral edema: report on 15 cases and review of the literature. Am. J. Clin. Oncol. 26, 247-251.